» Articles » PMID: 15140134

Different G Protein-coupled Signaling Pathways Are Involved in Alpha Granule Release from Human Platelets

Overview
Publisher Elsevier
Specialty Hematology
Date 2004 May 14
PMID 15140134
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Alpha granule release plays an important role in propagating a hemostatic response upon platelet activation. We evaluated the ability of various agonists to cause alpha granule release in platelets. Alpha granule release was measured by determining P-selectin surface expression in aspirin-treated washed platelets. ADP-induced P-selectin expression was inhibited both by MRS 2179 (a P2Y1 selective antagonist) and AR-C69931MX (a P2Y12 selective antagonist), suggesting a role for both Galpha(q) and Galpha(i) pathways in ADP-mediated alpha granule release. Consistent with these observations, the combination of serotonin (a Galpha(q) pathway stimulator) and epinephrine (a Galpha(z) pathway stimulator) also caused alpha granule release. Furthermore, U46619-induced P-selectin expression was unaffected by MRS 2179 but was dramatically inhibited by AR-C69931, indicating a dominant role for P2Y12 in U46619-mediated alpha granule release. Additionally, the Galpha(12/13)-stimulating peptide YFLLRNP potentiated alpha granule secretion in combination with either ADP or serotonin/epinephrine costimulation but was unable to induce secretion by itself. Finally, costimulation of the Galpha(i) and Galpha(12/13) pathways resulted in a significant dose-dependent increase in alpha granule release. We conclude that ADP-induced alpha granule release in aspirin-treated platelets occurs through costimulation of Galpha(q) and Galpha(i) signaling pathways. The P2Y12 receptor plays an important role in thromboxane A(2)-mediated alpha granule release, and furthermore activation of Galpha(12/13) and Galpha(q) signaling pathway can cause alpha granule release.

Citing Articles

The future of pharmacology and therapeutics of the arachidonic acid cascade in the next decade: Innovative advancements in drug repurposing.

Patrignani P, Contursi A, Tacconelli S, Steinhilber D Front Pharmacol. 2024; 15:1472396.

PMID: 39268466 PMC: 11390530. DOI: 10.3389/fphar.2024.1472396.


Cell Surface Platelet Tissue Factor Expression: Regulation by P2Y and Link to Residual Platelet Reactivity.

Brambilla M, Becchetti A, Rovati G, Cosentino N, Conti M, Canzano P Arterioscler Thromb Vasc Biol. 2023; 43(10):2042-2057.

PMID: 37589138 PMC: 10521789. DOI: 10.1161/ATVBAHA.123.319099.


Platelet P2Y signalling pathway in the dysregulated immune response during sepsis.

Amoafo E, Entsie P, Kang Y, Canobbio I, Liverani E Br J Pharmacol. 2023; 181(4):532-546.

PMID: 37525937 PMC: 10830899. DOI: 10.1111/bph.16207.


Clopidogrel Is Associated with Reduced Likelihood of Aneurysmal Subarachnoid Hemorrhage: a Multi-Center Matched Retrospective Analysis.

Hudson J, Nowicki K, Lucke-Wold B, Gersey Z, Dodd W, Alattar A Transl Stroke Res. 2023; 15(5):936-940.

PMID: 37470917 DOI: 10.1007/s12975-023-01179-9.


The Signaling Pathway of the ADP Receptor P2Y in the Immune System: Recent Discoveries and New Challenges.

Entsie P, Kang Y, Amoafo E, Schoneberg T, Liverani E Int J Mol Sci. 2023; 24(7).

PMID: 37047682 PMC: 10095349. DOI: 10.3390/ijms24076709.